What's in Almirall, S.A.'s pipeline?

Almirall, S.A. has 34 drugs in our index: 2 marketed, 0 filed, 9 in Phase 3, 15 in Phase 2, 8 in Phase 1.

Which companies overlap with Almirall, S.A.'s portfolio?

Top competitors by shared drug class: Galderma R&D, Arcutis Biotherapeutics, Inc., GlaxoSmithKline, Pfizer, Alfasigma S.p.A..

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/almirall-s-a.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-06-10 · How we verify

Almirall, S.A. — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Almirall, S.A. pipeline: 2 marketed, 0 filed, 9 Phase 3, 15 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 9 Phase 3 15 Phase 2 8 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
dapsone gel	dapsone gel	marketed	Sulfone [EPC]
Tirbanibulin ointment 1%	Tirbanibulin ointment 1%	marketed
vehicle of LAS41007	vehicle of LAS41007	phase 3	PDE4 inhibitor	PDE4	Respiratory
LAS41005	LAS41005	phase 3	Phosphodiesterase 4 (PDE4) inhibitor	PDE4	Immunology / Dermatology
LASW1510	LASW1510	phase 3	PDE4 inhibitor	PDE4	Immunology / Dermatology
dapsone gel vehicle	dapsone gel vehicle	phase 3	Sulfone antibiotic with anti-inflammatory properties	Dihydropteroate synthase; neutrophil function modulation	Dermatology
KX2-391 Ointment 1%	KX2-391 Ointment 1%	phase 3	Src kinase inhibitor	Src kinase	Dermatology
LAS41007	LAS41007	phase 3	Phosphodiesterase 4 (PDE4) inhibitor	PDE4	Immunology/Dermatology
LAS41008	LAS41008	phase 3	PDE4 inhibitor	PDE4	Immunology
LASW1835	LASW1835	phase 3	PDE4 inhibitor	PDE4	Respiratory/Pulmonology
LAS106521	LAS106521	phase 3	Phosphodiesterase 4 (PDE4) inhibitor	PDE4	Immunology / Dermatology

Therapeutic area mix

Immunology / Dermatology · 3
Dermatology · 2
Immunology · 1
Immunology/Dermatology · 1
Respiratory · 1
Respiratory/Pulmonology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Galderma R&D · 2 shared drug classes
Arcutis Biotherapeutics, Inc. · 2 shared drug classes
GlaxoSmithKline · 2 shared drug classes
Pfizer · 2 shared drug classes
Alfasigma S.p.A. · 1 shared drug class
Derm Research, PLLC · 1 shared drug class
Amgen · 1 shared drug class
Dr. Reddy's Laboratories Limited · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Almirall, S.A.:

Cite this brief

Drug Landscape (2026). Almirall, S.A. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/almirall-s-a. Accessed 2026-06-10.